Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial
Jeffrey A. Barnes(Harvard University), Jeremy S. Abramson(Massachusetts General Hospital), Robin Joyce(Beth Israel Deaconess Medical Center), Tak Takvorian, Ephraim P. Hochberg(Massachusetts General Hospital), James Weitzman(Massachusetts General Hospital), Eric D. Jacobsen(Dana-Farber Cancer Institute), Yang Feng(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Donna Neuberg(Otsuka (Japan))
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer
|Science|2017|1.6k